AstraZeneca PLC
LSE:AZN

Watchlist Manager
AstraZeneca PLC Logo
AstraZeneca PLC
LSE:AZN
Watchlist
Price: 10 256 GBX 0.12% Market Closed
Market Cap: 159B GBX
Have any thoughts about
AstraZeneca PLC?
Write Note

AstraZeneca PLC
Long-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

AstraZeneca PLC
Long-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
AstraZeneca PLC
LSE:AZN
Long-Term Investments
$1.9B
CAGR 3-Years
19%
CAGR 5-Years
5%
CAGR 10-Years
18%
GlaxoSmithKline PLC
LSE:GSK
Long-Term Investments
ÂŁ1.2B
CAGR 3-Years
-29%
CAGR 5-Years
-7%
CAGR 10-Years
-3%
Verona Pharma PLC
NASDAQ:VRNA
Long-Term Investments
$15m
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Indivior PLC
LSE:INDV
Long-Term Investments
$26m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Long-Term Investments
$63m
CAGR 3-Years
21%
CAGR 5-Years
16%
CAGR 10-Years
1%
Dechra Pharmaceuticals PLC
LSE:DPH
Long-Term Investments
ÂŁ14.9m
CAGR 3-Years
-5%
CAGR 5-Years
7%
CAGR 10-Years
N/A
No Stocks Found

AstraZeneca PLC
Glance View

Market Cap
159B GBX
Industry
Pharmaceuticals

AstraZeneca PLC stands as a formidable entity in the global pharmaceutical landscape, adeptly navigating the intricate dance of innovation and commerce. Emerging from a merger between Sweden's Astra AB and the UK's Zeneca Group in 1999, the company has carved a niche through its relentless pursuit of cutting-edge medical solutions. Central to its operations is a sophisticated ecosystem of research and development, where thousands of scientists tirelessly explore the expansive frontier of biotechnology. The lifeblood of AstraZeneca's growth is its robust pipeline, where potential life-saving medicines traverse an arduous journey from laboratory benches to clinical trials, and eventually, regulatory approval. This rigorous process underscores its commitment to addressing complex diseases in areas such as oncology, cardiovascular, and respiratory health – domains marked by high unmet medical needs and significant market demand. The commercial prowess of AstraZeneca is equally vital to its success narrative. With a global reach spanning over 100 countries, the company leverages its advanced production facilities and strategic partnerships to deliver its pharmaceutical breakthroughs to those in need. Revenue generation is predominantly through the sale of prescription drugs, with blockbuster medications serving as pivotal financial pillars. These products, once approved, are strategically marketed to healthcare providers, ensuring they gain traction in various markets. AstraZeneca's approach is finely tuned to balance the scale of mass production with the nuance of catering to specific regional demands, maintaining a competitive edge in a crowded pharmaceutical landscape. Through these intricacies of innovation, production, and strategic market positioning, AstraZeneca not only generates substantial revenues but also reinforces its mission to improve patient health outcomes worldwide.

AZN Intrinsic Value
14 313.88 GBX
Undervaluation 28%
Intrinsic Value
Price

See Also

What is AstraZeneca PLC's Long-Term Investments?
Long-Term Investments
1.9B USD

Based on the financial report for Jun 30, 2024, AstraZeneca PLC's Long-Term Investments amounts to 1.9B USD.

What is AstraZeneca PLC's Long-Term Investments growth rate?
Long-Term Investments CAGR 10Y
18%

Over the last year, the Long-Term Investments growth was 64%. The average annual Long-Term Investments growth rates for AstraZeneca PLC have been 19% over the past three years , 5% over the past five years , and 18% over the past ten years .

Back to Top